Minimally Invasive Suprachoroidal Drainage for the Treatment of Neovascular Glaucoma

NCT07201415 · tracked via the Priya Life Science China tracker

Sponsor

Zhongnan Hospital

Phase

N/A

Started

2025-01-01

Last updated

2025-10-01

Condition(s) studied

Neovascular Glaucoma

Investigational drug(s) / intervention(s)

minimally invasive suprachoroidal drainage

minimally invasive suprachoroidal drainage: minimally invasive suprachoroidal drainage

Study summary

To explore the efficacy and safety of minimally invasive suprachoroidal drainage for the treatment of advanced neovascular glaucoma

Eligibility

Sex

ALL

Min age

18 Years

Max age

85 Years

Healthy volunteers

Inclusion Criteria: * Advanced (angle-closure) neovascular glaucoma with poorly controlled intraocular pressure (IOP \> 21mmHg) after medical or surgical treatment Exclusion Criteria: * Various other types of glaucoma (including primary open-angle glaucoma, primary open-closed glaucoma, normal tension glaucoma, juvenile glaucoma, congenital glaucoma, other special types of glaucoma, etc.) * Eye infection within two weeks before surgery * Non-glaucomatous intraocular diseases that affect intraocular pressure (choroidal hemorrhage or detachment, retinal detachment, lens subluxation, thyroid eye disease, clinically significant macular edema, eye tumors, etc.) * Visual acuity of non-study eyes \< 0.05 * Congenital or acquired factors lead to ciliary body anatomical abnormalities

Primary outcome measure(s)

Ocular biological parameters — 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
intraocular pressure
Ocular biological parameters — 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
visual acuity
Surgical outcome measures — 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
use of intraocular pressure lowering drugs
The success rate of surgery was evaluated according to the specific value of intraocular pressure after surgery — 1 day, 1 week, 1 month, 3 months, and 6 months after surgery
Complete success was defined as IOP within the normal range with no drug dependence, conditional success was defined as IOP within the normal range with drug dependence, and failure was defined as the rest

Trial sites (1)

Facility	City	Region	Status
Zhongnan Hospital of Wuhan University	Wuhan	Hubei

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07201415 on ClinicalTrials.gov ↗ ← All trials in China